Abstract:Background/Purpose Age-associated B cells (ABCs) accumulate and contribute to the pathogenesis of systemic autoimmune diseases like lupus. Despite recent insights into the ontogeny and function of ABCs, the key transcriptional regulators of ABCs differentiation remain ill-defined. Addressing this gap in knowledge will reveal targets to enable the prevention or reduction of ABCs in disease therapy. Methods We employed single-cell RNA sequencing to identify transcription factors (TFs) that were differentially expressed in age-associated B cells (ABCs) from both lupus patients and lupus-prone mice. An arrayed CRISPR screen of these regulatory TFs was conducted under in-vitro conditions that induce ABC formation. In our cohort, we included patients diagnosed with Mowat-Wilson Syndrome (MWS), a condition attributed to ZEB2 haploinsufficiency. We constructed B-cell-specific Zeb2 knockout mice and subjected them to TLR7-driving and Bm12-transfer lupus models, enabling us to study Zeb2's regulatory role in ABC formation and associated autoimmunity. The detection of autoantibodies was achieved using an autoantigen microarray. To investigate Zeb2's direct targets, we performed ATAC-seq, Cut & Tag, and Cut & Run sequencing, and integrated these regulome findings with transcriptome data obtained from RNA sequencing. We employed trans-well and PHrodo staining techniques to study the distinct migratory and phagocytic features of ABCs. The induced lupus models were used to evaluate the potential of the JAK1/3 inhibitor tofacitinib in intervening with ABC formation and associated autoimmunity. Results We carried out a screening process and identified that Zeb2 is required for in-vitro differentiation of ABCs in both humans and mice. We observed a reduction in ABCs in individuals with ZEB2 haploinsufficiency and in mice devoid of Zeb2 in B-cells (figure 1). By utilizing mice that selectively lack Zeb2 in B cells, we demonstrated the essential role of Zeb2 in facilitating autoimmune pathology relevant to ABCs, including autoantibody formation, production of proinflammatory cytokines and chemokines, migration to end- organ tissues, and induction of tissue damage in a lupus model (figure 1). Zeb2 binds to the +20kb intronic enhancer of Mef2b, thereby repressing Mef2b-mediated germinal center B-cell differentiation and instead promoting ABC formation (figure 2). Zeb2 also targets genes crucial for ABC specification and function, including Itgax (figure 2). Furthermore, Zeb2 regulates the distinct cellular characteristics of ABCs, including their migration and phagocytic abilities. The differentiation of ABCs driven by Zeb2 necessitates Jak-Stat signaling. Notably, we found that the use of tofacitinib, an approved JAK1/3 inhibitor, effectively reduces the accumulation of ABCs in autoimmune mice and patients (figure 3). Conclusion Our study reveals that ABCs, a unique B cell subset, rely on Zeb2 expression and regulation. Zeb2 affects germinal center B cell development and dictates ABC identity. Modulating Zeb2-mediated Jak-Stat signaling could effectively curb ABC accumulation and related autoimmunity, presenting a potential therapy for autoimmune diseases.

Amelioration of Autoimmunity in a Lupus Mouse Model by Modulation of T‐Bet–Promoted Energy Metabolism in Pathogenic Age/Autoimmune‐Associated B Cells

LSO-001 Modulating T-bet-promoted Energy Metabolism in Pathogenic Age/autoimmune-Associated B Cells Ameliorates Lupus Autoimmunity

Metabolic regulation of follicular helper T cell differentiation in a mouse model of lupus

Excessive CD11c+Tbet+ B Cells Promote Aberrant TFH Differentiation and Affinity-Based Germinal Center Selection in Lupus.

Phenotypic and functional characteristics of murine CD11c+ B cells which is suppressed by metformin

B cell-intrinsic IFN-γ promotes excessive CD11c+ age-associated B cell differentiation and compromised germinal center selection in lupus mice

A global view of T cell metabolism in systemic lupus erythematosus

204 ZEB2 Acts As a Crucial Transcriptional Regulator Governing Age- Associated B Cell Formation and Pathogenicity in Systemic Lupus Erythematosus

Novel Mitophagy Inducer Alleviates Lupus Nephritis by Reducing Myeloid Cell Activation and Autoantigen Presentation.

Blockade of Macrophage Autophagy Ameliorates Activated Lymphocytes-Derived DNA Induced Murine Lupus Possibly Via Inhibition of Proinflammatory Cytokine Production.

T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy

T Cell Homeostatic Proliferation Promotes a Redox State That Drives Metabolic and Epigenetic Upregulation of Inflammatory Pathways in Lupus

A cellular overview of immunometabolism in systemic lupus erythematosus

Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1β pathways in MRL/lpr mice

Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27-IgD- Cells

Rab4A-directed endosome traffic shapes pro-inflammatory mitochondrial metabolism in T cells via mitophagy, CD98 expression, and kynurenine-sensitive mTOR activation

B Cell Metabolism in Autoimmune Diseases: Signaling Pathways and Interventions

Age-Associated B Cells (ABCs) in the Prognosis, Diagnosis and Therapy of Systemic Lupus Erythematosus (SLE)

Metabolic Alterations and Increased Liver mTOR Expression Precede the Development of Autoimmune Disease in a Murine Model of Lupus Erythematosus

Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis